Aybintio® (bevacizumab biosimilar)

About Organon

Organon is a publicly traded, diversified healthcare company that emerged as a spin-off from Merck & Co. (known as MSD outside the U.S. and Canada) in June 2021. The company's portfolio is built around three core pillars: a leading women's health franchise, a growing portfolio of biosimilars, and a stable of established brands across various therapeutic areas. With a global commercial footprint and a commitment to addressing unmet needs, particularly in women's health, Organon aims to drive sustainable growth through its existing portfolio, pipeline development, and strategic business development.

Therapeutic Areas

Other Oncology Drugs